Scott Palmer is a Respiratory physician. ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2100 Erwin Rd
Durham, NC 277100001
Telephone
919-620-4467Registry record last updated 22 Mar 2013.
Clinical trials
- Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Long Term Follow up of the LTOG Cohort
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year20254 payments$12,284openpaymentsdata.cms.gov ↗
- Incyte CorporationProgram year20252 payments
- ABBVIE INC.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
34.1%Short-acting sulfonamides15.4%Sulfamethoxazole-Trimethoprim100%Part D≥25 patientsMacrolide Antimicrobial12.9%Azithromycin100%Part D≥21 patients+ 1 more class in this area
Metabolism & gastrointestinal
25%Proton pump inhibitor13%Pantoprazole Sodium63%Esomeprazole Magnesium21%Omeprazole17%Part D<11 patientsCorticosteroid12%Prednisone100%Part D≥23 patientsNervous system
12%Gabapentinoids4.7%Gabapentin100%Part D<11 patientsOther antidepressants2.7%Mirtazapine100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
20 NIH research awards on record, funded 1996–2026 per NIH RePORTER. The latest:
- Duke Program of Training in Pulmonary ReSearch to Promote, Engage and Retain Academic Researchers (PROSPER)
Duke University
FY2026$433,453T32HL160494
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”